THERAPY DOSSIER · th-cb72ce321473

Sodium hydrosulphide, a hydrogen sulphide donor

Drug · H2S donor; not a discrete ChEMBL drug (nearest entry SODIUM SULFIDE, CHEMBL2107611)

Evidence & regulatory context

Mechanism: H2S donor; not a discrete ChEMBL drug (nearest entry SODIUM SULFIDE, CHEMBL2107611)
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: NaHS
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23806779 ↗2013Mixed findings

Effect of sodium hydrosulphide after acute compression injury of spinal cord.

RatSpinal cord injuryCompressionWistarMaleIntraperitoneal50 micromolar1 hour after injury

Model: Spinal cord clip compression injury at T8 to T10 after laminectomy, using a 35 g clip for 1 min; tissue collected 8 h after injury

Sodium hydrosulphide reduced nitric oxide by 27 per cent, lipid peroxide by 18 per cent, myeloperoxidase by 10 per cent and GFAP by 8 per cent, and increased glutathione by 44 per cent and Nrf-2 expression 1.8 fold relative to injury alone. There was no significant change in NF-200 and no evident m…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…